Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis

Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1149-54. doi: 10.1007/s00259-002-0859-5. Epub 2002 Jun 19.

Abstract

In a retrospective analysis of patients with sarcoma who underwent fluorodeoxyglucose positron emission tomography (FDG PET) imaging, tumor maximum FDG uptake was analyzed for ability to predict patient survival and disease-free interval. Two hundred and nine patients with sarcoma were imaged prior to treatment with neoadjuvant chemotherapy or resection. Tumor FDG uptake expressed as maximum standard uptake value (SUV(max)) was compared with disease-free and overall survival. A multivariate Cox regression analysis was applied to examine the role of SUV(max) in predicting time to death or disease progression, after adjusting for standard clinical prognostic factors. The multivariate analyses showed that the SUV(max) information is a statistically significant independent predictor of patient survival. Tumors with larger SUV(max) have a significantly poorer prognosis. This retrospective analysis indicates that the sarcoma tumor SUV(max) value determined by PET is an independent predictor of survival and disease progression.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biological Transport
  • Bone Neoplasms / diagnostic imaging*
  • Bone Neoplasms / mortality
  • Bone Neoplasms / pathology
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Fluorodeoxyglucose F18 / pharmacokinetics*
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Staging
  • Predictive Value of Tests
  • Prognosis
  • Regression Analysis
  • Retrospective Studies
  • Sarcoma / diagnostic imaging*
  • Sarcoma / mortality
  • Sarcoma / pathology
  • Soft Tissue Neoplasms / diagnostic imaging
  • Soft Tissue Neoplasms / mortality
  • Soft Tissue Neoplasms / pathology
  • Survival Analysis
  • Tissue Distribution
  • Tomography, Emission-Computed
  • Treatment Outcome

Substances

  • Fluorodeoxyglucose F18